Revelation Biosciences, Inc. (REVB) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Revelation Biosciences reported revenue of $0. Net income was -$8.9M, or -$23.95 per diluted share. Operating activities generated -$8.3M of cash, leaving -$8.3M of free cash flow. At fiscal year end, Revelation Biosciences held $11.6M in total assets against $2.7M in total liabilities, including $10.7M of cash and equivalents.
Open the full interactive Revelation Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Revelation Biosciences Key Stats
| Share Price | $0.73 |
|---|---|
| Market Cap | $2.8M |
| 52-Week Range | $0.73 – $5.44 |
| Shares Outstanding | 3.8 million (basic, 2026 Q2) |
Revelation Biosciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | — | — | -$10.9M | -$8.7M | -$8.0M | -$9.1M |
| Pre-Tax Income | -$136,408 | -$2.1M | -$10.8M | -$120,254 | -$15.0M | -$8.9M |
| Income Tax | — | — | $0 | $0 | $0 | $0 |
| Net Income | -$136,408 | -$2.1M | -$10.8M | -$120,254 | -$15.0M | -$8.9M |
| Diluted EPS | -$6048.00 | — | -$115718.40 | -$101.76 | -$1052.16 | -$23.95 |
Revelation Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.9M | -$2.5M | -$3.0M | -$3.3M |
| Diluted EPS | -$7.08 | -$4.04 | -$2.71 | -$0.87 |
Revelation Biosciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $11,734 | $78,532 | $5.3M | $12.0M | $6.5M | $10.7M |
| Current Assets | $651,291 | $83,366 | $5.4M | $12.1M | $6.6M | $10.8M |
| Total Assets | $74.2M | $48.4M | $5.5M | $12.2M | $6.6M | $11.6M |
| Current Liabilities | $33,772 | $5.5M | $4.5M | $5.6M | $1.9M | $2.0M |
| Total Liabilities | $2.9M | $8.4M | $4.5M | $5.6M | $1.9M | $2.7M |
| Shareholders' Equity | $5.0M | -$7.8M | $1.1M | $6.6M | $4.7M | $8.9M |
Revelation Biosciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$218,713 | -$725,618 | -$11.2M | -$7.3M | -$18.3M | -$8.3M |
| Cash From Investing | -$74.0M | $25.7M | — | — | -$19,171 | — |
| Cash From Financing | $74.3M | -$24.9M | $15.2M | $14.0M | $12.8M | $12.5M |
| Free Cash Flow | — | — | -$11.4M | — | -$18.3M | -$8.3M |
Figures from Revelation Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Revelation Biosciences financials page for every line item.
Revelation Biosciences Company Profile
| Ticker | REVB |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001810560 |
Frequently Asked Questions
What was Revelation Biosciences' revenue in fiscal 2025?
Revelation Biosciences (REVB) reported revenue of $0 for fiscal 2025.
What is Revelation Biosciences' annual revenue history?
Revelation Biosciences' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Revelation Biosciences' net income in fiscal 2025?
Revelation Biosciences reported net income of -$8.9M for fiscal 2025.
What was Revelation Biosciences' earnings per share (EPS) in fiscal 2025?
Revelation Biosciences' diluted EPS was -$23.95 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Revelation Biosciences generate in fiscal 2025?
Revelation Biosciences generated -$8.3M of free cash flow in fiscal 2025.
What was Revelation Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Revelation Biosciences reported revenue of $0.
How many shares of Revelation Biosciences are outstanding?
Revelation Biosciences reported a weighted average of 3.8 million basic shares outstanding in 2026 Q2.
What is Revelation Biosciences' market cap?
Based on its latest closing price, Revelation Biosciences (REVB) has a market capitalization of about $2.8M.
When does Revelation Biosciences' fiscal year end?
Revelation Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Revelation Biosciences headquartered?
Revelation Biosciences lists its business address in San Diego, California in its SEC filings.